Multi Baggers
Alembic Pharma
BSE ID : 533573 NSE ID : APLLTD
RECOMMENDED PRICE 70.85
PEAK FROM RECO 1150.00 1,523.15%
CURRENT PRICE 991.00 Resource id #14
Alembic Pharma continues to maintain its market share of 1.62% owing to its strong distribution reach, strong field force and product launches. We believe APL is trading at an attractive valuation at 9.03x and 7.25x of FY13EPS of Rs.7.85 and FY14EPS of Rs.9.77. We initiate a 'BUY' on the stock with a target price of Rs.90 (appreciation of about 27%) with the long term investment horizon.
Alembic Pharmaceuticals
Alembic Pharma (APL) continues to maintain its market share of 1.62% owing to its strong distribution reach, strong field force and product launches. It has four brands in the list of top 300 brands of industry i.e. 'Azithral', 'Roxid', 'Althrocin' and 'Wikoryl'.
On consolidated basis, the company has posted a rise of about 12% in its net profit at Rs.30.83 crore for the quarter ended June 2012 as compared to Rs.27.56 crore for the same quarter in the previous year. Total income has increased by 6.72% at Rs.366.77 crore for quarter as compared to Rs.343.67 crore for the quarter ended June 2011. R&D cost of the quarter was about 14 Crores, which is about 4.1% of sales. There was the loss of about Rs.3.5 Crores for the quarter largely on the forex denominated loans. Price increase growth is just above 2%, 9% is about volume growth and about 4% is new product introduction. EPS worked out to be 1.64 as against 1.46 for the last corresponding quarter.
The Domestic formulations business posted sales of Rs.197.24 crores against Rs.172.44 crores with a 14% growth over the corresponding quarter of the previous year. Export API recorded sales of Rs.83.48 crores against Rs.60.73 crores registering growth of 37% while domestic API recorded sales of Rs.30.47 crores against Rs.34.75 crores in like quarter last year. International Generic Formulation sales stood at Rs.46.05 crores against Rs. 61.15 crores over the corresponding quarter last year. De-growth was due to price erosion, product mix and capacity constraint.
Cumulative ANDA filings as on June 2012 stands at 49 of which 20 are already approved and cumulative DMF filings are at 63.
Valuation
With strong pipeline of ANDA filings, capacity expansion and sharp growth across business segments and positive guidance by management; Alembic Pharma Ltd. growth outlook looks strong. We believe APL is trading at an attractive valuation at 9.03x and 7.25x of FY13EPS of Rs.7.85 and FY14EPS of Rs.9.77. We initiate a 'BUY' on the stock with a target price of Rs.90 (appreciation of about 27%) with the long term investment horizon.
For full report, Click on the attachment
Disclaimer & Disclosure: This document is prepared for our clients only, on the basis of publicly available information and other sources believed to be reliable. Whilst we are not soliciting any action based on this information, all care has been taken to ensure that the facts are accurate, fair and reasonable. This information is not intended as an offer or solicitation for the purchase or sell of any financial instrument and at any point should not be considered as an investment advise. Reader is requested to rely on his own decision and may take independent professional advise before investing. Hem Securities Limited, Hem Finlease Private Limited, Hem Multi Commodities Pvt. Limited, Directors and any of its employees shall not be responsible for the content. The person accessing this information specifically agrees to exempt Hem Securities Limited, Hem Finlease Private Limited, Hem Multi Commodities Pvt. Limited or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and further agrees to hold Hem Securities Limited, Hem Finlease Private Limited, Hem Multi Commodities Pvt. Limited or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The companies and its affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material may from time to time, have long or short positions in, and buy or sell the securities there of, company (ies) mentioned here in and the same have acted upon or used the information prior to, or immediately following the publication.
AlembicPharma_HemSec_Multibagger.pdf
3200
Powerful mix of technical and commodity packs with timely expert.
Designed especially for traders looking to tap the profit opportunities of volatile markets.
Stay on top of the Indian Commodities Market with commodity trading calls Intraday, and Positional (Short & Long-Term Calls).
